ArticleVox sanguinis2026
Factors associated with aggregate formation in cold-stored platelets.
Article in Vox sanguinis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
BACKGROUND AND
objectivesCold-stored platelets (CSPs) can form aggregates, ultimately rendering them unusable. The causes of these aggregates and how to prevent them are poorly understood. This study aimed to identify potential factors associated with aggregate formation in CSPs stored in plasma for up to 14 days. MATERIALS AND
methodsWe obtained CSPs from 79 unique donors during a clinical trial. We retrospectively analysed aggregate rates among donors of different sexes, ages and blood groups. In a subgroup, samples were also tested by enzyme-linked immunosorbent assay for markers of thrombosis and inflammation. Platelets from mice lacking von Willebrand factor (VWF) and human apheresis platelets treated with VWF and caplacizumab were stored and assessed for platelet count and aggregate formation by visual inspection and flow cytometry.
resultsForty-five (57%) units developed aggregates, and 34 (43%) did not. Units with aggregates had significantly lower soluble thrombomodulin levels and higher VWF levels approaching significance. In a multivariate analysis, platelets from female donors and donors with ABO type A were significantly more likely to form aggregates than those from male donors and donors with ABO type O, respectively. In the oldest donor cohort, units with aggregates were significantly less common than those without. Interfering with VWF levels and VWF function during storage did not reliably cause or prevent aggregates.
conclusionDonor sex, age, ABO type and thrombomodulin were significantly associated with aggregate formation or prevention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.